Derek Raghavan
Overview
Explore the profile of Derek Raghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
6748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice?
Raghavan D, Symanowski J
JCO Oncol Pract
. 2025 Mar;
:OP2500117.
PMID: 40053893
No abstract available.
2.
Burgess E, Grigg C, Boselli D, Symanowski J, Golshayan A, Graham D, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102302.
PMID: 39903972
Background: Androgen receptor pathway inhibitors (ARPI) in combination with docetaxel (Doc) and androgen deprivation therapy (ADT) has improved outcomes for men with metastatic hormone sensitive prostate cancer (mHSPC). We hypothesized...
3.
Ghosh N, Matusz-Fisher A, Bose R, Boselli D, Magee G, Chen T, et al.
JCO Oncol Pract
. 2024 Nov;
:OP2400417.
PMID: 39556779
Purpose: Venetoclax has made a significant impact in the treatment of chronic lymphocytic leukemia (CLL) due to its ability to induce deep and durable remissions with a finite duration of...
4.
Burke J, Raghavan D
JCO Oncol Pract
. 2024 Nov;
20(11):1437-1440.
PMID: 39531851
No abstract available.
5.
Trump D, Raghavan D
JCO Oncol Pract
. 2024 Jul;
20(9):1152-1154.
PMID: 39008788
Oncologists use molecular prediction/pharmacogenomics to improve Rx of cancer. Voltaire now wrong.
6.
Brown L, Zhu J, Mauer E, Thiede S, Macera L, Stein M, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300378.
PMID: 38061006
Purpose: Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in the...
7.
8.
Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S, et al.
J Clin Oncol
. 2023 Jul;
41(22):3772-3781.
PMID: 37499357
Purpose: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of the primary...
9.
10.
Burgess E, Livasy C, Symanowski J, Matulay J, Grigg C, Clark P, et al.
Urol Oncol
. 2023 Jun;
41(8):357.e23-357.e29.
PMID: 37295980
Objectives: Novel regimens targeting immune checkpoints and the cMET or HER2 pathways are under investigation in metastatic urothelial carcinoma (mUC) though co-expression of these molecular targets has not been defined....